IL17A and colitis: The administration of ST28 by oral route demonstrated a significant improvement in the intestinal lesions caused by DSS, indicating a potential protective action against colitis’74 Following treatment with DSS, there was an observed increase in IL‐17 production in LPLs, suggesting the occurrence of an inflammatory response inside the intestinal region.